These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28538506)

  • 1. Allogeneic Hematopoietic Cell Transplantation for Dyskeratosis Congenita: A Report of 3 Cases.
    Tamura S; Imamura T; Urata T; Kobayashi M; Gen M; Tomii T; Do J; Osone S; Ishida H; Hosoi H; Kuroda H
    J Pediatr Hematol Oncol; 2017 Oct; 39(7):e394-e398. PubMed ID: 28538506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity conditioning-based hematopoietic cell transplantation for dyskeratosis congenita: Single-center experience and literature review.
    Bhoopalan SV; Wlodarski M; Reiss U; Triplett B; Sharma A
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29177. PubMed ID: 34086408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure.
    Ayas M; Nassar A; Hamidieh AA; Kharfan-Dabaja M; Othman TB; Elhaddad A; Seraihy A; Hussain F; Alimoghaddam K; Ladeb S; Fahmy O; Bazarbachi A; Mohamed SY; Bakr M; Korthof E; Aljurf M; Ghavamzadeh A
    Bone Marrow Transplant; 2013 Sep; 48(9):1168-72. PubMed ID: 23542225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.
    Nelson AS; Marsh RA; Myers KC; Davies SM; Jodele S; O'Brien TA; Mehta PA
    Biol Blood Marrow Transplant; 2016 May; 22(5):884-8. PubMed ID: 26845033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.
    Dietz AC; Orchard PJ; Baker KS; Giller RH; Savage SA; Alter BP; Tolar J
    Bone Marrow Transplant; 2011 Jan; 46(1):98-104. PubMed ID: 20383216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic cell transplantation in Fanconi anemia and dyskeratosis congenita: A minireview.
    Ayas M
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):285-289. PubMed ID: 28644950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita.
    Elmahadi S; Muramatsu H; Kojima S
    Curr Opin Hematol; 2016 Nov; 23(6):501-507. PubMed ID: 27607446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful T-cell-depleted haploidentical hematopoietic stem cell transplantation in a child with dyskeratosis congenita after a fludarabine-based conditioning regimen.
    Algeri M; Comoli P; Strocchio L; Perotti C; Corbella F; Del Fante C; Baio A; Giorgiani G; Gurrado A; Accornero E; Cugno C; Pession A; Zecca M
    J Pediatr Hematol Oncol; 2015 May; 37(4):322-6. PubMed ID: 25374286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Second Unrelated Donor Hematopoietic Stem Cell Transplant in a Patient With Dyskeratosis Congenital After First Graft Rejection.
    Giardino S; Faraci M; Lanino E; Morreale G; Terranova P; Palmisani E; Dufour C; Miano M
    Exp Clin Transplant; 2023 Apr; 21(4):368-374. PubMed ID: 28969530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse hemorrhagic colitis in a patient with dyskeratosis congenita after nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Ehlert K; Rossig C; Groll AH; Beyna T; Froehlich B; Juergens H
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e41-4. PubMed ID: 25000468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.
    Fioredda F; Iacobelli S; Korthof ET; Knol C; van Biezen A; Bresters D; Veys P; Yoshimi A; Fagioli F; Mats B; Zecca M; Faraci M; Miano M; Arcuri L; Maschan M; O'Brien T; Diaz MA; Sevilla J; Smith O; Peffault de Latour R; de la Fuente J; Or R; Van Lint MT; Tolar J; Aljurf M; Fisher A; Skorobogatova EV; Diaz de Heredia C; Risitano A; Dalle JH; Sedláček P; Ghavamzadeh A; Dufour C
    Br J Haematol; 2018 Oct; 183(1):110-118. PubMed ID: 29984823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita.
    Güngör T; Corbacioglu S; Storb R; Seger RA
    Bone Marrow Transplant; 2003 Mar; 31(5):407-10. PubMed ID: 12634734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen.
    Brazzola P; Duval M; Fournet JC; Gauvin F; Dalle JH; Champagne J; Champagne MA
    Bone Marrow Transplant; 2005 Dec; 36(12):1103-5; author reply 1105. PubMed ID: 16205731
    [No Abstract]   [Full Text] [Related]  

  • 15. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience.
    Strullu M; Rialland F; Cahu X; Brissot E; Corradini N; Thomas C; Blin N; Rialland X; Méchinaud F; Mohty M
    Eur J Haematol; 2012 Jun; 88(6):504-9. PubMed ID: 22372430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and genetic features of dyskeratosis congenita, cryptic dyskeratosis congenita, and Hoyeraal-Hreidarsson syndrome in Japan.
    Yamaguchi H; Sakaguchi H; Yoshida K; Yabe M; Yabe H; Okuno Y; Muramatsu H; Takahashi Y; Yui S; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Inokuchi K; Ito E; Ogawa S; Kojima S
    Int J Hematol; 2015 Nov; 102(5):544-52. PubMed ID: 26329388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
    Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrelated allogeneic hematopoietic stem cell transplantation in a patient with Revesz syndrome, a severe variant of dyskeratosis congenita.
    Watanabe K; Arakawa Y; Kambe T; Oguma E; Kishimoto H; Koh K
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27476. PubMed ID: 30259646
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.